binarypublishTLDR:
- Biotech startup Moonwalk Biosciences has raised $57 million in seed and series A financing to advance its epigenetic profiling and engineering technology platform and therapeutics for various medical conditions.
- Moonwalk Biosciences’ technology involves making edits in the epigenome without altering the DNA sequence itself, reducing the risks associated with gene editing.
Biotech startup Moonwalk Biosciences has secured $57 million in seed and series A financing to support the development of its epigenetic profiling and engineering technology platform and therapeutics for a range of medical conditions. The funding round was led by Alpha Wave Ventures, with participation from ARCH Venture Partners, Future Ventures, GV, Khosla Ventures, and YK Bioventures.
Moonwalk Biosciences is focused on developing effective and safe epigenetic medicines that utilize comprehensive insights on cellular epigenetics. Epigenetic changes can potentially reverse disease, opening up new possibilities for potential cures. Moonwalk’s technology enables edits in the epigenome without altering the primary DNA sequence, minimizing the risks associated with gene editing.
Moonwalk Biosciences was founded by Feng Zhang, Arash Jamshidi, Justin Valley, and Dr. Alex Aravanis. Dr. Aravanis, the former chief technology officer of Illumina and Grail, also serves as the company’s CEO.
Epigenetics has emerged as a promising field in biotechnology, offering new approaches to understanding and potentially treating various diseases. Moonwalk Biosciences’ innovative technology and significant financing will enable further advancements in this space and potentially pave the way for groundbreaking therapies.
